Juvenile Macular Degeneration (Stargardt Disease) – Detailed Analysis report

April 11, 2017

Key Players Copernicus Therapeutics Inc , Grupo Ferrer Internacional SA, Iris Pharma

The latest Pharmaceutical and Healthcare disease pipeline guide Juvenile Macular Degeneration – Pipeline Review, H1 2017, provides an overview of the Juvenile Macular Degeneration (Ophthalmology) pipeline landscape.

Juvenile macular degeneration is a series of inherited eye disorders that affects children and young adults. The most common form of juvenile macular degeneration is Stargardt disease. Stargardt’s disease is an inherited autosomal recessive syndrome. Signs and symptoms include blurry or fuzzy vision, dark, empty spots in the center of vision and difficulty reading or performing detail work. Risk factors include arteriosclerosis, hypercholesterolemia, smoking and hypertension.

Request a sample report @ https://www.htfmarketreport.com/sample-report/322002-juvenile-macular-degeneration

Advertisements

New technology is helping people with vision impairments see

January 30, 2016

The digitalized glasses help some people with low vision,see.
The Sight Center of Northwest Ohio hosted demonstrations of the new glasses today.

The glasses are hands-free, mobile and they’re customized to each person’s needs. They are for people with visual impairments like macular degeneration.The glasses help with things like reading as well as using laptops and phones.

esight 2

Jill Hofbauer has Stargardt’s Disease, a form of macular degeneration. Today, she put on a pair of eSight glasses and things came into focus. She was able to read a menu without having it up close to her face and she read the eye chart much further down than usual, “When I was doing the number charts and they showed me how far down the chart I got, I was amazed. Without the glasses I would have been taxed to see that information.”

Here’s how the glasses work. A camera records high definition video.
The video is then presented on two screens in the headset.
eSight users carry a small, lightweight processing controller that adjusts every pixel of the video in real time. Hugh Montgomery is with the company,”We can add zoom, we can add contrast. It does auto focus so I am basically watching a video of my life when i use the glasses.”

It is NOT cheap. The system goes for $15,000. That is the cost of a nice second hand car. How much is vision worth?

For more info:

http://www.13abc.com/home/headlines/New-technology-is-helping-people-with-vision-impairments-see-366614781.html

http://www.esighteyewear.com/


A Possible Cure For Blindness: The Ocata Stem Cells

October 4, 2015
  • Ocata has developed methods to culture and deliver retinal progenitor cells.
  • Early, unpublished animal data suggest retinal progenitors can reverse blindness caused by degenerative diseases.
  • If shown effective, the retinal cells have a huge number of potential applications.
  • Ocata has received funding for retinal progenitor development in the orphan disease retinitis pigmentosa.
  • Retinitis pigmentosa has no approved, effective therapy, and represents a potential market over $1 billion per year.

Ocata Therapeutics  has stated in no uncertain terms that its embryonic stem cell -derived retinal pigmented epithelium (RPE) is its major program, and it has the potential to address an array of macular disorders, including age-related macular degeneration, Stargardt’s disease, macular edema, and myopic macular degeneration.

for more info:

http://seekingalpha.com/article/3542846-a-possible-cure-for-blindness-the-ocata-preclinical-pipeline-photoreceptor-progenitors


DaVinci vs. Prodigy

August 14, 2015

There was a time when a digital Image magnifier was a simple device. You put a newspaper on a table and an enlarged view appeared on a video screen. Now the number of screen options and alternative features require a guide book. However this flexibility does provide a far superior experience.

Two of the best are the DaVinci by Enhanced Vision and the Prodigy by Humanware.  They both provide an enlarged vision of what you are trying to read in high definition with optional magnification, contrast and type color. They both can read the message out loud for you. They both help you see photos of you grandkids, although in different manners.

The differences between these magical devices are in the hardware construction.

Da Vinci

The DaVinci has a camera on a stand that swivels left and right, forward and back.  This allows a woman to point it at her own eyes as she applies makeup. It allows a student to point it at the blackboard and read the magnified image on the monitor.

The DaVinci lets you connect to your computer or your iPhone, allowing you to read the iPhone screen on your enlarged monitor. It can read your email aloud. You can wander thru Google or watch YouTube on an enlarged screen.

Prodigi

prodigi 2

The Prodigy has a removable camera similar to a smart phone. This gives you the advantage of having two devices in one: a desktop magnifier and a portable magnifier. The portable feature lets you read menus in a restaurant or info at the airport. However this is not a tablet or smartphone.

They both have easy to use controls. The DaVinci has familiar buttons and knobs. The Prodigy has a simple touch screen.

With a 24 inch screen, the DaVinci costs $2,995 and the Prodigy Costs $3,495. For $595 you can buy a Pebble portable magnifier and add it to the DaVinci.

Either one of these devices is a wonderful assistive, well made, expensive, but well worth the cost.


Positive Results for Macular Degeneration Stem Cell Research

June 28, 2015

Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, announced positive results.

The results of these trials in 31 patients with dry Age-related Macular Degeneration (AMD) and Stargardt’s Macular Dystrophy (SMD) provide additional evidence supporting the safety and tolerability of hESC-derived retinal pigment epithelium (RPE). Some patients were followed for up to 4 years and none of the patients showed evidence of hyperproliferation, rejection or serious adverse ocular or systemic safety issues related to the transplanted tissue.

The abstract reported that all of the patients, 26 from the US studies and 5 from the South Korean study, experienced improved or stable, best-corrected visual acuity (BCVA). These studies suggest that hESC-derived cells could provide a potentially safe new source of cells for regenerative medicine.

for more info:

http://www.businesswire.com/news/home/20150624005284/en/Ocata-Therapeutics-Announces-Positive-Results-Reported-Late#.VY_a2PlViko


A Note from Lauren Tappan

May 4, 2015

I have Stargardt’s and know that recent research has shown that people with Stargardt’s have problems digesting and absorbing Vitamin A.

I recently purchased a bottle of saffron 20/20. The Canadian company that produces this supplement suggested that this product might not be the best one for people with Stargardt’s because it has additional Vitamin A supplement included in the product.

So I continue to take pure saffron capsules which I have found to be very helpful. I believe it has helped to improve my reading acuity and overall health. So, I pass this anecdotal information on to our blog readers. Thank you.


Stem Cells Allow Nearly Blind Patients to See

April 2, 2015

In a report published in the journal Lancet, scientists led by Dr. Robert Lanza, chief scientific officer at Advanced Cell Technology, provide the first evidence that stem cells from human embryos can be a safe and effective source of therapies for two types of eye diseases—age-related macular degeneration, the most common cause of vision loss in people over age 60, and Stargardt’s macular dystrophy, a rarer, inherited condition that can leave patients legally blind and only able to sense hand motions.

The trial is the only one approved by the Food and Drug Administration involving human embryonic stem cells as a treatment. (Another, the first to gain the agency’s approval, involved using human embryonic stem cells to treat spinal cord injury, but was stopped by the company.) Because the stem cells come from unrelated donors, and because they can grow into any of the body’s many cells types, experts have been concerned about their risks, including the possibility of tumors and immune rejection.

For more info:  http://time.com/3507094/stem-cells-eyesight/